Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined with Temozolomide and Etoposide in Recurrent Medulloblastoma
NCT04501718Phase 2Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Oct 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in medulloblastoma, sponsored by Beijing Sanbo Brain Hospital. Started Oct 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04501718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501718.